Filing Flows › AstraZeneca (AZN) › Q1 2026 › vs Q1 2025
AstraZeneca (AZN) Q1 2026 vs Q1 2025 (year over year)
AstraZeneca's revenue rose $1.7B (+13%) from $13.6B in Q1 2025 to $15.3B in Q1 2026. Gross margin 82.5% against 83.5% (-1.0 pts).
AstraZeneca, Q1 2026: revenue $15.3B (+12% year over year), operating margin 27.8%, net earnings $3.1B, operating cash flow $4.3B. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Gross margin | 82.5% | 83.5% | -1.0 pts |
| Operating margin | 27.8% | 27.0% | +0.7 pts |
| Net margin | 20.2% | 21.5% | -1.3 pts |
| Free cash flow margin | 24.7% | 29.9% | -5.2 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $15.3B | $13.6B | $1.7B | +13% |
| Gross profit | $12.6B | $11.3B | $1.3B | +11% |
| Cost of revenue | $2.7B | $2.2B | $437M | +20% |
| Operating profit | $4.2B | $3.7B | $572M | +16% |
| Operating expenses | $8.4B | $7.7B | $691M | +9% |
| Pre-tax earnings | $3.9B | $3.4B | $512M | +15% |
| Other expense, net | $332M | $272M | $60.0M | +22% |
| Net earnings | $3.1B | $2.9B | $160M | +5% |
| Income tax | $833M | $481M | $352M | +73% |
| Working capital & other | $1.2B | $1.6B | −$332M | -21% |
| Operating cash flow | $4.3B | $4.5B | −$172M | -4% |
| Free cash flow (OCF − capex) | $3.8B | $4.1B | −$290M | -7% |
| Capital expenditures | $547M | $429M | $118M | +28% |
Questions
How much did AstraZeneca's revenue grow year over year in Q1 2026?
AstraZeneca's revenue rose $1.7B (+13%) from $13.6B in Q1 2025 to $15.3B in Q1 2026. Gross margin 82.5% against 83.5% (-1.0 pts).